<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96615">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847014</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-402</org_study_id>
    <nct_id>NCT01847014</nct_id>
  </id_info>
  <brief_title>Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument</brief_title>
  <acronym>SYMPHONYext</acronym>
  <official_title>AC-055-402: An Extension of AC-055-401, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm,
      Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to
      psychometrically validate the PAH-SYMPACT instrument. The objective is to assess the
      long-term safety of macitentan in subjects with PAH beyond the treatment in the AC-055-401
      study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol-defined criterion of macitentan availability achieved.
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events, serious adverse events, marked laboratory abnormalities and adverse events leading to study drug discontinuation from Baseline to Week 16.</measure>
    <time_frame>Visit 1 to Post-treatment safety follow-up visit (30 days after discontinuation of the study drug)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macitentan tablet, dose of 10 mg, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan</intervention_name>
    <description>Macitentan tablet, dose of 10 mg, once daily.</description>
    <arm_group_label>Macitentan</arm_group_label>
    <other_name>ACT-064992</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure.

          -  Patients with PAH who completed study AC-055-401

          -  Women of childbearing potential must:

          -  Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum
             pregnancy tests.

          -  Agree to use two methods of contraception from Visit 1 until 1 month after study drug
             discontinuation.

        Exclusion Criteria:

          -  Patients who prematurely discontinued study drug in study AC-055-401

          -  Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to
             become pregnant during the study

          -  Known hypersensitivity to macitentan or its excipients or drugs of the same class
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Romero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Actelion Pharmaceuticals US, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Palmer, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Actelion Pharmaceuticals US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carl &amp; Edyth Lindner Center for Research &amp; Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 8, 2016</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension (PAH)</keyword>
  <keyword>psychometric instrument</keyword>
  <keyword>PAH-SYMPACT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
